Questions and Controversies in Treating Breast Cancer

EP. 1: FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

EP. 2: CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

EP. 3: Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

EP. 4: Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

EP. 5: Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

EP. 6: Sequencing in Hormone-Driven Metastatic Breast Cancer

June 16th 2017

EP. 7: PI3K Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

EP. 8: Adjuvant Therapy for HER2-Driven Breast Cancer

June 16th 2017

EP. 9: Extended Adjuvant Therapy for HER2-Positive Breast Cancer

June 16th 2017

EP. 10: APHINITY Trial in HER2+ Breast Cancer

June 16th 2017

EP. 11: Pending FDA Approval of Neratinib in HER2+ Breast Cancer

June 16th 2017

EP. 12: Adjuvant Therapy for High-Risk HER2+ Breast Cancer

June 16th 2017

EP. 13: Triple-Positive Metastatic Breast Cancer

June 16th 2017

EP. 14: Brain Metastases in HER2-Positive Breast Cancer

June 16th 2017

EP. 15: Metastatic Triple-Negative Breast Cancer

June 16th 2017

EP. 16: BRCA-Mutated Triple-Negative Breast Cancer

June 16th 2017

EP. 17: PARP Inhibitors for BRCA-Mutated TNBC

June 16th 2017

EP. 18: Immunotherapy for Triple-Negative Breast Cancer

June 16th 2017

EP. 19: Final Thoughts on Progress in Breast Cancer Research

June 16th 2017

EP. 20: Options With CDK4/6 in HR+ Metastatic Breast Cancer

June 16th 2017

NEXT PAGE
PREVIOUS PAGE